Predictors of survival in patients with bone metastasis of lung cancer

Clinical Orthopaedics and Related Research

Volumn 466, Issue 3, 2008, Pages 729-736

  Sugiura, Hideshi ^a   Yamada, Kenji ^a   Sugiura, Takahiko ^b   Hida, Toyoaki ^a   Mitsudomi, Tetsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b Aichi Circulation and Respiratory Center ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; PACLITAXEL; VINORELBINE DITARTRATE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; HER1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; ADENOCARCINOMA; BONE TUMOR; CANCER STAGING; DRUG ANTAGONISM; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 42449116658     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-007-0051-0     Document Type: Article

References (21)

1. Agarwala AK, Hanna NH. Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy. Clin Lung Cancer. 2005;6:367-368.
2. Ando M, Ando Y, Sugiura S, Minami H, Saka H, Sakai S, Shimokata K, Hasegawa Y. Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Jpn J Cancer Res. 1999;90:249-253.
3. Batson OV. The function of vertebral veins and their role in spread of metastases. Ann Surg. 1940;112:138-149.
4. Freise G, Gabler A, Liebig S. Bronchial carcinoma and long-term survival: retrospective study of 433 patients who underwent resection. Thorax. 1978;33:228-234.
5. Hansen BH, Keller J, Laitinen M, Berg P, Skjeldal S, Trovik C, Nilsson J, Walloe A, Kalén A, Wedin R. The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl. 2004;75:11-15.
6. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20:3815-3825.
7. Hirano Y, Oda M, Tsunezuka Y, Ishikawa N, Watanabe G. Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg. 2005;11:401-404.
8. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137-139.
9. Johnston AD. Pathology of metastatic tumors in bone. Clin Orthop Relat Res. 1970;73:8-32.
10. Katagiri H, Takahashi M, Wakai K, Sugiura H, Kataoka T, Nakanishi K. Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br. 2005;87:698-703.
11. Matsuyama W, Yamamoto M, Machida K, Mitsuyama H, Watanabe M, Higashimoto I, Osame M, Arimura K. [Two lung adenocarcinoma patients with multiple brain metastasis treated with gefitinib and surviving more than 2 years] (in Japanese). Nihon Kokyuki Gakkai Zasshi. 2006;44:653-658.
12. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513-2520.
13. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
15. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65:25-32.
16. Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med. 1975;16:986-989.
17. Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H, Ohsaka S. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine. 1990;15:1110-1113.
18. Tomita K, Kawahara N, Baba H, Tsuchiya H, Nagata S, Toribatake Y. Total en bloc spondylectomy for solitary spinal metastases. Int Orthop. 1994;18:291-298.
19. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine. 2001;26:298-306.
20. van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW. Dutch Bone Metastasis Study Group. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer. 2005;103:320-328.
21. Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer. 2007;7:51.